|
 All Upcoming Events In Biotechnology - February 17, 2012
- Price: $80
Add to Cart
30 Upcoming Events Without Opinion - February 17, 2012
- Price: $10
Add to Cart
30 Upcoming Events With Opinion - February 17, 2012
- Price: $300
Add to Cart
New BioMedicine Top 10 Gainers - February 20, 2010
- Price: $10
Add to Cart
New BioMedicine Top 10 Losers - February 20, 2010
- Price: $10
Add to Cart
|
| |
Calendar |
| |
We offer 5 types of Calendars / Tables:
1) All Upcoming Events in Biotechnology: a list of the key Upcoming Events for Biotechnology companies. Calendar provides Expected Date of the Event, Company name, Nature of the Event, Drug name and the Disease Indication. It also lists if New BioMedicine has covered the event and issued an Opinion on the outcome of the event.
2) 30 Upcoming Events WITH Opinion: a list of 30 Upcoming Events for Biotechnology companies expected within the next 3 months that have been covered by New BioMedicine. The Calendar provides Expected Date of the Event, Company name, Nature of the Event, Drug name, the Disease Indication, and our Opinion (Positive or Negative) on the expected outcome of the event. It also lists the estimated Peak Sales to Market Cap. percentage to ascertain the importance of the event to the company.
3) 30 Upcoming Events WITHOUT Opinion: a list of 30 Upcoming Events for Biotechnology companies expected within the next 3 months that have been covered by New BioMedicine. The Calendar provides Expected Date of the Event, Company name, Nature of the Event, Drug name and the Disease Indication. It also lists the estimated Peak Sales to Market Cap. percentage to ascertain the importance of the event to the company.
4) Top 10 Gainers: List of the stocks covered by New BioMedicine that have experienced the highest percentage returns from our coverage date till the date when the results of the expected event was reported. Table provides Company name, Details of the Event, Date on which New BioMedicine issued its coverage, our Expectations during the coverage, Result date, Result of the event, Price of the Stock when New BioMedicine issued its coverage, Opening Price after Result, and Net Return.
5) Top 10 Losers: List of the stocks covered by New BioMedicine that have experienced the highest percentage losses from our coverage date till the date when the results of the expected event was reported. Table provides Company name, Details of the Event, Date on which New BioMedicine issued its coverage, our Expectations during the coverage, Result date, Result of the event, Price of the Stock when New BioMedicine issued its coverage, Opening Price after Result, Net Return and the Reason for the Negative Returns. |
| |
SAMPLE TABLE UPCOMING EVENTS (WITHOUT OPINION)
| EVENT DATE |
COMPANY |
INDICATION |
EVENT |
REPORT DATE |
REPORT DATE PRICE |
| January 19, 2012 (Expected in Mid February 2012) |
Cell Therapeutics, Inc.
(CTIC) |
Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) |
CHMP review of Pixuvri |
January 5, 2012 |
$1.12 |
| Mid - Late February 2012 |
Threshold Pharmaceuticals
(THLD) |
Pancreatic cancer |
Phase II trial data of TH-302 |
February 7, 2012 |
$3.38 |
| February 17, 2012 |
Corcept Therapeutics Incorporated
(CORT) |
Cushing's Syndrome |
FDA approval of Korlym |
December 30, 2011 |
$3.44 |
| February 22, 2012 |
VIVUS Inc.
(VVUS) |
Obesity |
FDA Endocrinologic and Metabolic Drugs Advisory Committee review of Qnexa |
February 13, 2012 |
$12.34 |
| February 23, 2012 |
Chelsea Therapeutics
(CHTP) |
Neurogenic Orthostatic Hypotension (NOH) |
FDA panel review of Northera |
February 13, 2012 |
$4.99 |
| February - March 2012 |
Regeneron Pharmaceuticals Inc.
(REGN) |
First-line Metastatic Androgen-Independent Prostate Cancer |
Final data from third Phase III (VENICE) trial data of Aflibercept combination with docetaxel/prednisone |
January 11, 2012 |
$74.44 |
| February - March 2012 |
ImmunoGen, Inc.
(IMGN) |
Second-line HER2 Positive Metastatic Breast Cancer (MBC) |
Phase III EMILIA trial data of Trastuzumab-DM1 (T-DM1) |
January 13, 2012 |
12.30 |
| February - March 2012 |
Synta Pharmaceuticals Corp
(SNTA) |
Non-Small Cell Lung cancer (NSCLC) |
Interim results from first-stage Phase IIb portion of Phase IIb/III GALAXY trial of Ganetespib with docetaxel in NSCLC |
January 17, 2012 |
$4.61 |
| February - March 2012 |
Nektar Therapeutics (NKTR) |
Second-line Ovarian Cancer |
Detailed data from the Phase II trial of NKTR-102 |
January 24, 2012 |
$6.00 |
| March 6, 2012 |
Discovery Laboratories, Inc.
(DSCO) |
Prevention of Respiratory Distress Syndrome (RDS) in premature infants |
FDA approval for Surfaxin |
February 2, 2012 |
$2.23 |
SAMPLE TABLE UPCOMING EVENTS (WITH OPINION)
| EVENT DATE |
COMPANY |
INDICATION |
EVENT |
REPORT DATE |
REPORT DATE PRICE |
PEAK SALES / MARKET CAPITAL (%) |
OPINION |
| January 19, 2012 (Expected in Mid February 2012) |
Cell Therapeutics, Inc. (CTIC)
|
Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) |
CHMP review of Pixuvri |
January 5, 2012 |
$1.12 |
54.11% |
Positive |
| Mid - Late February 2012 |
Threshold Pharmaceuticals (THLD) |
Pancreatic cancer |
Phase II trial data of TH-302 |
February 7, 2012 |
$3.38 |
180.91% |
Positive |
| February 17, 2012 |
Corcept Therapeutics Incorporated
(CORT) |
Cushing's Syndrome |
FDA approval of Korlym |
December 30, 2011 |
$3.44 |
172.61% |
Positive |
|
|
|
Sample Report:
VRTX's HCV drug Telaprevir received FDA approval on May 23, 2011. New BioMedicine had issued a report on this event on May 3, 2011. To read more about the drug, the disease, the market, the competition, etc. access it at the link below.
|
| |
Basket Reports: |
 |
Specific theme-based reports at a value price
|
View Package |
|
|
